Core Viewpoint - The announcement details the launch of the CIB CSI Technology Advantage Growth 50 Strategy ETF, which will be listed on the Shanghai Stock Exchange on February 27, 2026, with the full disclosure available on the company's website and the China Securities Regulatory Commission's fund electronic disclosure website [1][2]. Group 1: Fund Information - The fund will open for regular subscription and redemption on normal trading days of the Shanghai and Shenzhen Stock Exchanges, with specific times outlined in the prospectus or related announcements [2]. - The minimum subscription unit for the fund is set at 1 million shares, and the fund manager may adjust this based on operational and market conditions [3][4]. - The fund manager can impose limits on daily subscription amounts and individual investor holdings to protect existing shareholders' interests [3][4]. Group 2: Fees and Charges - Subscription and redemption agents may charge a commission of up to 0.50% on the subscription amount, which includes fees from the stock exchange and registration institutions [5][7]. - The minimum redemption unit is also set at 1 million shares, with similar conditions for adjustments as in the subscription process [6]. Group 3: Fund Sales and Management - Investors must conduct subscription and redemption transactions through designated agents, which include various securities firms listed in the announcement [8]. - The fund manager is required to disclose the net asset value of the fund shares on the next trading day after transactions are processed [9][10]. Group 4: Additional Information - The announcement emphasizes that the fund's management will adhere to principles of honesty and diligence but does not guarantee profits or minimum returns [1][19]. - Investors are encouraged to read the fund contract, prospectus, and product information documents for detailed information [11].

每经讯，2026年2月12日，北交所上市公司科力股份（920088，收盘价：42.91元）登上龙虎榜，交易方式是连续竞价，披露原因 是当日换手率达到22.61%，成交数量718.67万股，成交金额3.19亿元。买一席位为机构专用，买入889.31万元；卖一席位为国信 证券股份有限公司深圳互联网分公司，卖出724.1万元。 | | 2026-02-12科力股份 (920088) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | | | | ポリ | 机构专用 | 8893102.04 | 6861671.92 | | 买2 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 4779846.68 | 4938207.38 | | 买3 | 国信证券股份有限公司青岛分公司 | 4040013.86 | 0 | | 24 | 中国中金财富证券有限公司肥东公园路证券营业部 | 3971507.96 | 0 | | નેર | 国信证券股份有限公司深圳互联网分公司 | 3801508.81 | 7241001.52 | | 卖T | 国信证券股份有限公司深圳 ...

Group 1 - The company announced that starting from February 11, 2026, investors can open accounts, subscribe, redeem, and perform regular investment and conversion operations for certain funds through Chuangjin Qifu [1] - The company has signed a supplementary sales agreement with Beijing Chuangjin Qifu Fund Sales Co., Ltd. to enhance service offerings to investors [1] - Investors can enjoy fee discounts when subscribing or performing regular investment and conversion operations through Chuangjin Qifu, with the specifics determined by Chuangjin Qifu [2] Group 2 - The company will suspend subscription, conversion, and regular investment operations for the Ping An Jin Guanjia Money Market Fund from February 12 to February 23, 2026, while redemption and conversion out operations will continue [4][6] - The Ping An Zhongzheng Interbank Certificate of Deposit AAA Index 7-Day Holding Period Securities Investment Fund will also suspend similar operations during the same period [8][10] - The company will resume these operations on February 24, 2026, and will not issue further announcements regarding this resumption [4][8] Group 3 - The company has appointed Fangzheng Securities Co., Ltd. as a liquidity service provider for the Ping An Hang Seng Hong Kong Stock Connect Technology Theme ETF, effective February 11, 2026 [12] - The company has announced the establishment of the Ping An New Sharp Quantitative Stock Selection Mixed Fund, with the fund contract becoming effective on February 11, 2026 [21][22] - The company will handle subscription and redemption operations for the new fund within three months of the fund contract's effectiveness [22]

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -102 million RMB and -147 million RMB, indicating a reduction in losses by 143.6 million RMB to 188.6 million RMB compared to the previous year, representing a year-on-year loss reduction of 49% to 65% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -106 million RMB and -151 million RMB, with a loss reduction of 149.2 million RMB to 194.2 million RMB compared to the previous year, also reflecting a year-on-year loss reduction of 50% to 65% [1] - The company's operating revenues for 2022, 2023, and 2024 were 559 million RMB, 394 million RMB, and 546 million RMB respectively, with net profits attributable to shareholders of -15.15 million RMB, -54.18 million RMB, and -291 million RMB for the same years [1] IPO and Fundraising - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 21, 2022, with an initial public offering of 40.01 million shares, accounting for 10% of the total shares post-IPO, at a price of 33.57 RMB per share [2] - On the first day of trading, the stock reached a maximum price of 51.88 RMB, but is currently in a state of decline [3] - The total funds raised from the IPO amounted to 1.343 billion RMB, with a net amount of 1.221 billion RMB after deducting issuance costs, exceeding the original plan by 640 million RMB [3] Use of Proceeds - The company plans to use the raised funds for the research and industrialization of high-performance power management chips for consumer electronics and communication devices, the development of next-generation automotive and industrial power management chips, the establishment of a headquarters base, and for working capital [3] Underwriters and Shareholding - The total issuance costs amounted to 122 million RMB, with underwriting and sponsorship fees of 102 million RMB received by the underwriters [4] - The joint lead underwriters, including Guolian Minsheng Securities and China International Capital Corporation, received allocations of 1.6004 million shares each, representing 4% of the total shares issued [4]

1.公告基本信息 ■ 2.申购、赎回业务的办理时间 登录新浪财经APP 搜索【信披】查看更多考评等级 公告送出日期：2026年2月5日 根据《海富通鼎丰定期开放债券型发起式证券投资基金基金合同》（以下简称"《基金合同》"）及《海 富通鼎丰定期开放债券型发起式证券投资基金招募说明书》（以下简称"《招募说明书》"），本基金以 定期开放的方式运作。本基金的封闭期为自《基金合同》生效之日起（包括《基金合同》生效之日）或 自每一开放期结束之日次日起（包括该日）至该封闭期首日的3个月对日的前一日止。本基金的首个封 闭期为自《基金合同》生效之日起（包括《基金合同》生效之日）至基金合同生效日的3个月对日的前 一日止。第二个封闭期为首个开放期结束之日次日起（包括该日）至该封闭期首日的3个月对日的前一 日止，以此类推。本基金封闭期内不办理申购与赎回业务，也不上市交易。本基金自每个封闭期结束之 后第一个工作日起进入开放期，期间可以办理申购与赎回业务。 本基金的基金合同生效日为2018年11月2日，经前期运作，根据本基金《基金合同》、《招募说明书》 的规定，基金管理人决定自2026年2月6日起（含该日）至2026年2月12日（含该日 ...

特此公告。 富国基金管理有限公司 | HERRUN) | 胰菌膏苯 | | --- | --- | | N=7H | 1.50% | | 7 HONE 30 H | 0.75% | | 50日≤N<180日 | 0.50% | | No=180 H | 0 | | HERRANA | 相同型率 | | --- | --- | | N<7H | 1:50% | | 7 LINK 30 H | 0.75% | | 30 日本N~90日 | 0.50% | | N290 H | 000 | | 中国会副M(合中期费) | 品脂膏素 (通过直销中心申购的养老会等) | 申閲妙景 (其德投资者) | | --- | --- | --- | | M<300万元 | 0.15% | 1.90 | | M2500 7991: | 链累1000元 | | | 基金公家 | 你都只和提合到正要投资基金 | | --- | --- | | 基金属序 | 家国内流程合 | | 基金制代码。 | 025717 | | 最安端下方式 | 知约最开放式 | | 被波片同生数日 | 2025年11月5日 | | 去会管理人公募 | 第三基金 ...

银华多利宝货币市场基金B类基金份额恢复部分 代销机构的机构投资者大额申购（含定期定额投资及转换转入）业务的公告 ■ 注：1、银华基金管理股份有限公司决定2026年1月27日起（含2026年1月27日）恢复招商银行股份有限 公司的机构投资者办理银华多利宝货币市场基金B类基金份额10万元以上的大额申购（含定期定额投资 及转换转入）业务，敬请投资者留意。 2、在恢复招商银行股份有限公司的机构投资者正常办理银华多利宝货币市场基金B类基金份额10万元 以上的大额申购（含定期定额投资及转换转入）业务期间，机构投资者可分别从兴业银行股份有限公 司、中国邮政储蓄银行股份有限公司、中信银行股份有限公司、平安银行股份有限公司、中国民生银行 股份有限公司、宁波银行股份有限公司、中国建设银行股份有限公司、江苏银行股份有限公司、通华财 富(上海)基金销售有限公司、蚂蚁（杭州）基金销售有限公司、上海攀赢基金销售有限公司、浙江同花 顺基金销售有限公司和其他代销机构分别办理不超过10万元的申购（含定期定额投资及转换转入）业 务。如单日每个基金账户的申购申请、转换转入、定期定额投资单笔或累计金额超过以上情况，本基金 管理人有权拒绝。针对单笔申 ...

证券代码：601995 证券简称：中金公司 公告编号：临2026-002 特此公告。 中国国际金融股份有限公司 中国国际金融股份有限公司 关于全资子公司中国中金财富证券有限公司2025年度主要财务数据的公告 中国国际金融股份有限公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国外汇交易中心暨全国银行间同业拆借中心的相关规定，中国国际金融股份有限公司（以下简 称"公司"）全资子公司中国中金财富证券有限公司（以下简称"中金财富"）将于中国货币网 （www.chinamoney.com.cn）披露其2025年度未经审计的母公司资产负债表、利润表及净资本计算表。 上述报表为中金财富未经审计的单体报表，不包括中金财富合并范围内的子公司数据。公司现将中金财 富2025年度未经审计的母公司主要财务数据披露如下： 一、中金财富2025年度未经审计的母公司主要财务数据 截至2025年12月31日，中金财富总资产204,051,686,642.62元（人民币，下同），净资产 22,437,196,926.77元；2025年1-12月实现营业收 ...

截至2025年12月31日，中金财富总资产人民币2040.5亿元，净资产人民币224.37亿元；2025年1-12月实 现营业收入人民币83.49亿元(其中：手续费及佣金净收入人民币53.4亿元，利息净收入人民币17.6亿 元，投资收益人民币9亿元，公允价值变动收益人民币3.18亿元)，营业支出人民币60.3亿元，营业利润 人民币23.2亿元，利润总额人民币22.8亿元，净利润人民币17.6亿元。追加内容 本文作者可以追加内容哦 ! 格隆汇1月19日丨中金公司(03908.HK)公告，根据中华人民共和国外汇交易中心暨全国银行间同业拆借 中心的相关规定，公司的全资附属公司中国中金财富证券有限公司将于中国货币网 (www.chinamoney.com.cn)披露其2025年度未经审计的母公司资产负债表、利润表及净资本计算表。上 述报表为中金财富未经审计的单体报表，不包括中金财富合并范围内的子公司数据。中金财富年度财务 报表所载中金财富于截至2025年12月31日止年度未经审计的母公司主要财务数据如下： ...

Group 1 - The company, Beixin Life (688712.SH), plans to publicly issue 57 million shares, accounting for 13.67% of the total share capital after the issuance [1] - The initial strategic placement will involve 11.4 million shares, representing 20% of the total issuance, with senior management and core employees participating in a special asset management plan for 5.7 million shares, which is 10% of the total issuance [1] - The initial strategic placement by the sponsoring institution, China International Capital Corporation Wealth Securities Co., Ltd., is expected to be 2.85 million shares, or 5% of the total issuance, with a subscription amount not exceeding 40 million yuan [1] Group 2 - The company specializes in innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, recognized as a national high-tech enterprise [2] - The core products include the intravascular ultrasound (IVUS) diagnostic system, the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the flow reserve fraction (FFR) measurement system, the first domestic product in the FFR field approved by the same authority [2] - The company reported net profits attributable to the parent company of -290 million yuan, -140 million yuan, -43.596 million yuan, and 49.4496 million yuan for the years 2022 to the first half of 2025, with an expected profit of 78 million to 88 million yuan for 2025, representing a growth of 278.91% to 301.85% compared to the previous year [2] - The total planned investment of 952 million yuan from the fundraising will be allocated to the construction of an interventional medical device industrialization base, research and development projects, and to supplement working capital [2]